OLMA vs PFE
OLMA: Olema Pharmaceuticals is developing a next-generation endocrine therapy for breast cancer, headlined by its late-stage small molecule candidate, palazestrant. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | OLMA | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $7.05 | $29.85 | |
| Market cap | $617M | $170.1B | |
| P/E as of 2026-10-21 | n/a | 39.28 | |
| Net margin FY2025, SEC XBRL | n/a | +12.4% | |
| ROE FY2025, SEC XBRL | -33.9% | +9.0% | PFE higher |
| ROA FY2025, SEC XBRL | -30.5% | +3.7% | PFE higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-28 | n/a | 0.74 | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | -1.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -14.8% | |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-02 | 0.91 | 0.38 | |
| 1-year return as of 2026-10-21 close | -14.9% | +20.1% | PFE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.